BioPharmSignal logoBioPharmSignal

Biotech News

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex (VCNX)VaccinexCompany update

ROCHESTER, N.Y. , Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Vaccinex

Vaccinex is a biotechnology company focused on antibody therapies and immunology, with a history of pursuing difficult oncology and neurodegenerative targets. Its story is tied to platform science and the challenge of turning it into durable value.

Recent company news

VCNXVaccinex2026-04-30 00:05 EST

Vaccinex Reports 2025 Annual Financial Results

VCNXVaccinex2025-12-23 13:01 EST

Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease

VCNXVaccinex2025-05-27 12:45 EST

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNXVaccinex2025-04-21 12:45 EST

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab’s Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

VCNXVaccinex2025-03-07 22:15 EST

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Stock data

Close
0.78 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States